11 * В рамките на 60 дни след достигане на важен момент (във връзка с лекарствената безопасност или минимизирането на риска) * По поискване от EMEA
In addition, an updated RMP should be submitted * When new information is received that may impact on the current Safety Specification, Pharmacovigilance Plan or risk minimisation activities * Within 60 days of an important (pharmacovigilance or risk minimisation) milestone being reached ''. * At the request of the EMEA.